美国成人HIV感染者进入关怀时即启动普遍早期治疗与一般人群的五年死亡率比较
研究纳入美国82 766名进入HIV关怀的成人,用逆概率权重估计普遍早期治疗下的5年死亡率,并与匹配的美国一般人群比较。1999-2017年全期,HIV感染者5年死亡率较一般人群预期高7.9%(95%CI 7.6%-8.2%);普遍早期治疗下该升高为7.2%(95%CI 5.8%-8.6%)。2011-2017年,观察治疗模式下升高2.6%(95%CI 2.0%-3.3%),普遍早期治疗下为2.1%(95%CI 0.0%-4.2%)。结论认为扩大早期治疗可能适度降低但不能消除HIV感染者的死亡率升高。
要点
- 1999-2017年,HIV感染者5年死亡率较一般人群预期高7.9%(95%CI 7.6%-8.2%)。
- 普遍早期治疗下,全期死亡率升高为7.2%(95%CI 5.8%-8.6%),较观察模式略低。
- 2011-2017年,观察模式升高2.6%(95%CI 2.0%-3.3%),普遍早期治疗下2.1%(95%CI 0.0%-4.2%)。
核心结论
- 扩大早期治疗可能适度降低但不能消除HIV感染者相对美国一般人群的5年死亡率升高。
研究设计与样本
- 研究纳入在美国北美艾滋病队列协作(NA-ACC)临床站点进入HIV关怀的82 766名成人。
- 计算观察治疗模式下进入关怀后5年死亡率,并用逆概率权重估计普遍早期治疗(进入关怀3个月内启动抗逆转录病毒治疗)下的死亡率。
- 利用美国国家卫生统计中心数据构建按关键特征匹配的美国一般人群队列作为比较。
主要发现
- 整个研究期间(1999-2017年),HIV感染者5年死亡率较美国一般人群预期高7.9%(95%CI 7.6%-8.2%)。
- 普遍早期治疗下,HIV感染者死亡率升高为7.2%(95%CI 5.8%-8.6%)。
- 最近 examined 日历期间(2011-2017年),观察治疗模式下死亡率升高2.6%(95%CI 2.0%-3.3%),普遍早期治疗下为2.1%(95%CI 0.0%-4.2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mortality among adults with human immunodeficiency virus (HIV) remains elevated over those in the US general population, even in the years after entry into HIV care. We explore whether the elevation in 5-year mortality would have persisted if all adults with HIV had initiated antiretroviral therapy within 3 months of entering care. METHODS: Among 82 766 adults entering HIV care at North American AIDS Cohort Collaboration clinical sites in the United States, we computed mortality over 5 years since entry into HIV care under observed treatment patterns. We then used inverse probability weights to estimate mortality under universal early treatment. To compare mortality with those for similar individuals in the general population, we used National Center for Health Statistics data to construct a cohort representing the subset of the US population matched to study participants on key characteristics. RESULTS: For the entire study period (1999-2017), the 5-year mortality among adults with HIV was 7.9% (95% confidence interval [CI]: 7.6%-8.2%) higher than expected based on the US general population. Under universal early treatment, the elevation in mortality for people with HIV would have been 7.2% (95% CI: 5.8%-8.6%). In the most recent calendar period examined (2011-2017), the elevation in mortality for people with HIV was 2.6% (95% CI: 2.0%-3.3%) under observed treatment patterns and 2.1% (.0%-4.2%) under universal early treatment. CONCLUSIONS: Expanding early treatment may modestly reduce, but not eliminate, the elevation in mortality for people with HIV.
引用
- Edwards JK, Cole SR, Breger TL, et al. Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared With the General US Population. Clin Infect Dis. 2022. PMID: 34983066. doi:10.1093/cid/ciab1030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。